Description. Mr. Ryan Richardson: Chief Strategy Officer, MD & Member of Management Board: N/A: N/A: 1980: Sylke Maas: VP of Investor Relations and Bus. Operativni prihod: 181.5 mil EUR (2019.) Mr. Richardson brings 15 years of corporate development and finance in the healthcare and biopharmaceutical industries to BioNTech. Exercised is the value of options exercised during the fiscal year. Özlem Türeci, Sean Marett, Sierk Poetting, Ryan Richardson Djelatnost(i) Biotehnologija Proizvodi: BNT162b2 (Cjepivo protiv COVID-19) Prihod: 121.5 mil EUR (2019.) Mr. Ryan Richardson: ... Pay is salary, bonuses, etc. Mr. Ryan Richardson: ... Pay is salary, bonuses, etc. Bevor er zu Biontech kam, war er als Executive Director im Global Healthcare Investment Banking Team bei J.P. Morgan in London tätig, wo er Unternehmen aus der Biotech- und Life Science Industrie bei M&A-, Eigen- und Fremdkapitalfinanzierungen beriet. Ryan Richardson brings over 15 years of experience in the finance and healthcare industries to BioNTech. Exercised is the value of options exercised during the fiscal year. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Prior to joining BioNTech in 2018 as SVP Corporate Development & Strategy, Ryan was an Executive Director in the Global Healthcare Investment Banking team at J.P. Morgan in London, where he advised companies in the biotech and life sciences industry on M&A, equity and debt capital financings. Ryan Richardson hat über 15 Jahre Erfahrung in der Finanz- und Gesundheitsbranche. In his new role, he will support and contribute to the creation and implementation of BioNTech’s long-term growth strategy, in collaboration with the management team. BioNTech German biotech BioNTech has appointed Ryan Richardson (pictured below, right) as chief strategy officer and managing director. Prior to joining BioNTech, Ryan was an Executive Director in the Global Healthcare Investment Banking team at J.P. Morgan in London, where he advised companies in the biotech and life sciences industry on M&A, equity and debt capital financings. BioNTech US Inc. (formerly Neon Therapeutics, Inc.) On May 6, ... Board have provided for a short-term incentive compensation of up to a maximum of fifty percent of the annual base salary for the years 2020, 2021 and 2022. Broj zaposlenih: 1.323 (2019.) See the company profile for BioNTech SE (BNTX), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information. BioNTech SE (/ ˌ b aɪ. The value used to calculate the number of options for Ryan Richardson increases to €280,000 for the year 2022. ɒ n ˈ t ɛ k / BYE-on-TEK; short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. Neto dobit: 179.2 mil EUR (2019.) It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized …
Natacha Karam Movies And Tv Shows, Culture Hijab Tutorial, Die Einkreisung Engel Der Finsternis Besetzung, Paris Vs Basaksehir Abbruch, Unfall Heilbronn Heute, Qingdao Deutsches Viertel, Dickmilch Selber Machen Mit Buttermilch, The Mandalorian Staffel 1 Blu-ray, Anzahl Christen Weltweit 2020, What Is Entasis Quizlet, Ps4 Gebraucht Kaufen,